Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer - Full Text View

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00024076

Purpose

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Condition	Intervention	Phase
Lung Cancer Malignant Mesothelioma Metastatic Cancer Thymoma and Thymic Carcinoma	Procedure: radiofrequency ablation	Phase II

MedlinePlus related topics:

Cancer Lung Cancer Mesothelioma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Radiofrequency Ablation of Pulmonary Malignancy

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

July 2001

Detailed Description:

OBJECTIVES:

Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
Determine the efficacy of this treatment, in terms of local control, in these patients.
Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of a primary or secondary intrathoracic malignancy
- Any cell type or origin
- Involving the intrapulmonary, mediastinal, or pleural/chest wall
- Inoperable primary or metastatic cancer to the lung
Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
Single or multiple lesions that are non-contiguous with vital structures or organs such as:
- Trachea
- Heart
- Aorta
- Great vessels
- Esophagus
Less than 5 cm in largest dimension
Accessible via percutaneous transthoracic route

PATIENT CHARACTERISTICS:

Age:

Not specified

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Coagulation profile normal

Renal:

Not specified

PRIOR CONCURRENT THERAPY:

See Disease Characteristics

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00024076

Locations


United States, California
	Jonsson Comprehensive Cancer Center, UCLA
	Los Angeles, California, United States, 90095-1781

Sponsors and Collaborators

Jonsson Comprehensive Cancer Center

National Cancer Institute (NCI)

Investigators


Study Chair:	Robert D. Suh, MD	Jonsson Comprehensive Cancer Center

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000068889, UCLA-9908024, NCI-G01-2011
First Received:	September 13, 2001
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00024076
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

recurrent non-small cell lung cancer

recurrent small cell lung cancer

recurrent malignant mesothelioma

recurrent thymoma and thymic carcinoma

stage IIIB non-small cell lung cancer

stage IV non-small cell lung cancer

pulmonary carcinoid tumor

lung metastases

Study placed in the following topic categories:

Thoracic Neoplasms

Non-small cell lung cancer

Recurrence

Carcinoma

Carcinoid tumor

Carcinoma, Small Cell

Respiratory Tract Diseases

Lung Neoplasms

Lung Diseases

Thymoma

Thymus Neoplasms

Neoplasm Metastasis

Mesothelioma

Carcinoid Tumor

Adenoma

Carcinoma, Non-Small-Cell Lung

Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Respiratory Tract Neoplasms

Neoplastic Processes

Neoplasms

Pathologic Processes

Neoplasms by Site

Neoplasms by Histologic Type

Neoplasms, Mesothelial

Neoplasms, Complex and Mixed

ClinicalTrials.gov processed this record on September 23, 2008